Today’s Stock Alert: What Will Happen to Dynavax Technologies Corporation Next? The Stock Just Declined A Lot

Today's Stock Alert: What Will Happen to Dynavax Technologies Corporation Next? The Stock Just Declined A Lot

The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) is a huge mover today! About 1.65M shares traded hands. Dynavax Technologies Corporation (NASDAQ:DVAX) has declined 74.37% since April 27, 2016 and is downtrending. It has underperformed by 79.59% the S&P500.
The move comes after 8 months negative chart setup for the $171.07M company. It was reported on Nov, 30 by Barchart.com. We have $3.96 PT which if reached, will make NASDAQ:DVAX worth $13.69M less.

Analysts await Dynavax Technologies Corporation (NASDAQ:DVAX) to report earnings on March, 14. They expect $-0.86 earnings per share, down 22.86% or $0.16 from last year’s $-0.7 per share. After $-0.90 actual earnings per share reported by Dynavax Technologies Corporation for the previous quarter, Wall Street now forecasts -4.44% EPS growth.

Dynavax Technologies Corporation (NASDAQ:DVAX) Ratings Coverage

Out of 2 analysts covering Dynavax Technologies (NASDAQ:DVAX), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Dynavax Technologies has been the topic of 4 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The firm has “Neutral” rating given on Wednesday, April 27 by JP Morgan. RBC Capital Markets initiated Dynavax Technologies Corporation (NASDAQ:DVAX) rating on Monday, November 30. RBC Capital Markets has “Outperform” rating and $48 price target. The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) has “Sector Perform” rating given on Thursday, April 28 by RBC Capital Markets. The firm has “Hold” rating given on Wednesday, August 12 by Zacks.

According to Zacks Investment Research, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.”

Insitutional Activity: The institutional sentiment increased to 1.28 in Q2 2016. Its up 0.26, from 1.02 in 2016Q1. The ratio increased, as 18 funds sold all Dynavax Technologies Corporation shares owned while 34 reduced positions. 10 funds bought stakes while 43 increased positions. They now own 31.67 million shares or 4.27% less from 33.08 million shares in 2016Q1.
Susquehanna Llp holds 89,798 shares or 0% of its portfolio. Citadel Advisors has invested 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). California State Teachers Retirement System has invested 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). Fmr Ltd Co has 1.96M shares for 0% of their US portfolio. Millennium Limited Liability Company last reported 84,506 shares in the company. Great West Life Assurance Can has invested 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). Manufacturers Life Com The last reported 0% of its portfolio in the stock. Cam Grp A S holds 189,962 shares or 0.05% of its portfolio. Broadfin Ltd Liability Corp last reported 0.78% of its portfolio in the stock. Boston Prtn has 123,378 shares for 0% of their US portfolio. Tiaa Cref Mgmt Llc last reported 136,296 shares in the company. The New York-based Mhr Fund Management Limited Liability Company has invested 0.06% in Dynavax Technologies Corporation (NASDAQ:DVAX). California Employees Retirement Sys holds 0% or 14,300 shares in its portfolio. Cormorant Asset Management Ltd Liability holds 635,000 shares or 1.31% of its portfolio. Deutsche Fincl Bank Ag last reported 391,982 shares in the company.

More notable recent Dynavax Technologies Corporation (NASDAQ:DVAX) news were published by: Seekingalpha.com which released: “SD-101: The Other Side Of Dynavax” on November 30, 2016, also Prnewswire.com with their article: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” published on November 14, 2016, Investorplace.com published: “Why Dynavax Technologies Corporation (DVAX), Petroleo Brasileiro SA Petrobras …” on November 14, 2016. More interesting news about Dynavax Technologies Corporation (NASDAQ:DVAX) were released by: Seekingalpha.com and their article: “Does Dynavax Need A Partner?” published on November 30, 2016 as well as 247Wallst.com‘s news article titled: “Why Dynavax Shares Are in Freefall” with publication date: November 14, 2016.

DVAX Company Profile

Dynavax Technologies Corporation (Dynavax), incorporated on November 6, 2000, is a clinical-stage biopharmaceutical company. The Firm uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. The Company’s development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). The Company’s lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. The Company’s SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. The Company’s advanced inflammatory disease candidate is AZD1419. The Company’s pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment